Heart failure & cardiomyopathies
Effect of Sacubitril/Valsartan on Functional and Structural Cardiac Parameters in Adults With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Controlled Trial
Authors' conclusion
Although LCZ696 treatment did not improve pVO2 after 50 weeks, the favorable cardiac structural remodeling suggests a potential benefit in this patient group.
Study context
- Population
- Adults with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) and reduced exercise capacity (% predicted peak oxygen consumption ≤80%)
- Participants
- 40 adults
- Comparison
- Sacubitril/valsartan vs placebo
- Primary endpoint
- Change from baseline in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing
- Follow-up
- 50 weeks
Methodological detailsphase II, multicenter, double-blinded, placebo-controlled
- Phase II
- Multicenter
- Double-blinded
- Placebo-controlled
Primary result
As reported in the abstract
No difference in change from baseline in pVO2 between LCZ696 and placebo
P = 0.55
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Interventricular septal thickness · 50 weeks · decrease with LCZ696 | difference 4.7 mm | P = 0.0001 |
| LV mass index · 50 weeks · decrease with LCZ696 | difference 22.5 g/m² | P = 0.02 |
Composite z-score of clinically important nHCM parameters
- Improved with LCZ696, driven by wall thickness, LV mass index and troponin
- P = 0.015
Safety
Mild to moderate hypotension and mild renal impairment
- Rates similar to those in prior LCZ696 HF studies
Original publication
Effect of Sacubitril/Valsartan on Functional and Structural Cardiac Parameters in Adults With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Controlled Trial. JACC Heart Fail. Published 18 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it